Corcept Therapeutics Incorporated (CORT) — Federal Circuit affirms noninfringement ruling for Teva’s generic Korlym

What Happened

Legal development: On February 19, 2026, Corcept announced that the U.S. Court of Appeals for the Federal Circuit found that Teva’s marketing of generic Korlym (mifepristone) does not infringe two Corcept patents and affirmed a December 2023 district-court verdict, leaving the noninfringement result in place. (1) (2) (7)
Legal Development Details: The dispute concerned Teva’s marketing under U.S. Patents 10,195,214 and 10,842,800, which cover methods of co-administering Korlym with drugs that inhibit CYP3A4. The Federal Circuit affirmed the finding that Teva did not infringe the two patents. The announcement reported no damages, payments, royalties, injunctions, or new operating restrictions. (1) (2)

Trading Background

CORT remained heavily repriced after the December 31 relacorilant CRL, with shares still about 43% below the pre-CRL level despite a January 22 rebound following positive ROSELLA overall-survival results. A further decline after FDA’s corrected CRL highlighted continued hypercortisolism regulatory risk, leaving the stock entering the patent-dispute trigger with depressed expectations partly offset by stronger ovarian-cancer evidence. (3) (4) (5)

Confirmed Information Based on Disclosures

Patent scope: The patents concern methods of co-administering Korlym with CYP3A4-inhibiting drugs, including drugs commonly prescribed to patients with Cushing’s syndrome; the announcement does not identify patent validity or enforceability as issues decided. (1) (2)
Pre-existing competition: Teva’s generic launched in January 2024 and was already being marketed before the appellate update. Korlym was an established commercial product immediately before the event. (6)
Reported remedies: Corcept’s announcement identifies no damages, payment, royalty, injunction, or new operating restriction. (1) (2)

Key Missing Information

Appellate opinion and mandate: Corcept’s announcement does not reproduce the Federal Circuit opinion’s detailed reasoning or claim-specific scope and does not discuss mandate status. (1) (2)
Korlym commercial exposure: Continued Teva generic competition could pressure Korlym’s price, volume, and gross profit, though the magnitude remains uncertain. (6)

Company's Response

CEO Joseph K. Belanoff said Corcept was disappointed, would “vigorously defend” its rights, and was considering the best way to pursue judicial review. The company has stated an intention and an active consideration, not reported a filing or a court’s acceptance of further review. (1)

News Release Framing Risks

No material news-release framing risk was identified.

Analytical Interpretation

Pre-event expectation snapshot: Immediately before the cutoff, Korlym was an established commercial hypercortisolism product, Teva’s generic was already being marketed, and the Federal Circuit appeal had been argued on July 7, 2025 with a decision pending; no specific outcome expectation or quantified incremental commercial exposure had been established. (6)
Post-event change of expectation: The Federal Circuit’s reported affirmance establishes noninfringement for Teva’s marketing under the two patents, but, because no specific litigation-outcome expectation was established, the event’s change relative to prior expectations cannot be measured. (1) (2)
Integrated assessment:
- The affirmance leaves Corcept with a narrower opportunity in this case to use the two patents to stop Teva’s specified marketing; no separate payment or conduct restriction is reported, so the immediate effect is reduced patent-based blocking optionality rather than a new cash outflow or operating change. (1) (2)
- Teva’s generic competition predated the appellate decision. The ruling therefore confirms the existing competitive state and makes that marketing less vulnerable to reversal through this case; it does not initiate a new generic entry. (6) (2)
- Continued competition could affect Korlym through price, volume, and gross profit. Corcept’s 4.9% operating margin for the quarter ended September 30, 2025 indicates that a material product effect could matter to operating earnings, but is sensitivity context—not evidence that this ruling caused a loss. (6)
- Further judicial review remains a possible path, not a filed proceeding. A filing alone would not change the result; subsequent court action would have to alter the affirmance, and any later restriction would require an effective remedy. (1) (2)
- The reported decision is confined to Teva’s marketing under the two identified patents; it does not establish a broader loss of Corcept’s intellectual-property protection or an effect on other products or pipeline programs. (2) (6)
- Overall implication of this event: Corcept’s legal position narrowed as the affirmance reduced its ability to challenge Teva’s existing generic marketing under the two patents; the principal company-level channel is continued Korlym competition and potential product-level revenue and gross-profit pressure, while the event’s incremental financial significance depends on Korlym’s commercial sensitivity and whether further review changes the result. (1) (2) (6)